Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
IKKβ Inhibitor
BOT-64 is a selective IκB kinase β (IKKβ) inhibitor with an IC50 value of 1 µM. This compound effectively inhibits lipopolysaccharide-induced activation of nuclear factor-κB (NF-κB) and the subsequent transcription of NF-κB-regulated inflammatory genes. BOT-64 is valuable for research into inflammatory pathways and NF-κB signaling, providing insights into potential therapeutic strategies for inflammatory diseases. -
IKK-2 Inhibitor
IKK2-IN-4 is a selective inhibitor of IKK-2, exhibiting a potent IC50 value of 25 nM. This compound effectively inhibits LPS-induced TNFα production in peripheral blood mononuclear cells (PBMCs), making it a valuable tool for studying inflammatory responses. Research applications include investigations into signaling pathways involved in inflammation and potential therapeutic strategies for immune-related disorders. -
IKK Inhibitor
HPN-01 is a potent and selective inhibitor of IκB kinase (IKK), demonstrating pIC50 values of 6.4, 7.0, and <4.8 for IKK-α, IKK-β, and IKK-ε, respectively. This compound exhibits significant selectivity, showing more than 50-fold preference over a diverse panel of over 50 kinases, including ALK5, CDK-2, EGFR, ErbB2, GSK3β, PLK1, Src, and VEGFR-2. HPN-01 is a valuable tool for research applications focused on inflammatory pathways, cancer cell signaling, and the study of immune responses. -
ikkβ Inhibitor
IKKβ-IN-4 is a selective inhibitor of IkappaB kinase-β (IKKβ), with an IC50 value of 1.9 μM. IKKβ plays a crucial role in the NF-κB signaling pathway, which is implicated in various diseases, including inflammation and cancer. This compound is utilized in research to study the modulation of NF-κB activity and its potential therapeutic applications in related disease models. -
IKKβ Inhibitor
MLN120B dihydrochloride is a potent inhibitor of IKKβ, exhibiting competitive ATP binding with an IC50 of 60 nM. This compound effectively inhibits the growth of multiple myeloma cells both in vitro and in vivo, making it a valuable tool for cancer research. Additionally, MLN120B can be utilized in studies focused on rheumatoid arthritis, contributing to the understanding of inflammatory pathways and potential therapeutic interventions. -
IKK2 Inhibitor
IKK2-IN-3 is a selective inhibitor of IKK2, demonstrating a potent inhibitory effect with an IC50 value of 0.075 μM. This compound effectively disrupts the NF-κB signaling pathway, impacting various cellular processes such as inflammation and immune response. IKK2-IN-3 is suitable for research applications involving the modulation of IKK2 activity in disease models and studying the role of NF-κB in cellular signaling. -
IKK2 Inhibitor
LY2409881 is a selective inhibitor of IκB kinase β (IKK2), demonstrating potent inhibition with an IC50 of 30 nM. This compound is primarily used in research for its ability to modulate the NF-κB signaling pathway, making it relevant for studying inflammation, cancer, and autoimmune diseases. Researchers utilize LY2409881 to explore its therapeutic potential in various disease models and to investigate the role of IKK2 in cellular processes. -
IκB Kinase-2 Inhibitor
PS-1145 dihydrochloride is a selective inhibitor of IκB kinase-2, exhibiting an IC50 value of 88 nM. This compound effectively inhibits the phosphorylation of IκB kinase, thereby suppressing NF-κB activity. PS-1145 dihydrochloride is utilized in research applications targeting inflammatory responses and cancer biology. -
IKK2 Inhibitor
IKK-IN-4 is a selective inhibitor of IkappaB kinase 2 (IKKβ), exhibiting an IC50 of 45 nM for IKKβ and 650 nM for IKKα. This compound is instrumental in research focusing on the NF-κB signaling pathway and its regulation, providing insights into inflammation, cancer, and other diseases linked to IKK activity. IKK-IN-4 serves as a valuable tool for studying IKKβ-mediated signaling mechanisms and potential therapeutic interventions. -
TBK1/IKKi Dual Inhibitor
SR8185 is a potent dual inhibitor of TBK1 and IKKi, exhibiting IC50 values of 3 nM and less than 10 nM, respectively. This compound demonstrates significant antiproliferative effects across a wide range of human cancer cell lines. SR8185 is ideal for exploring cancer-related pathways and therapeutic strategies in cancer research. -
IKKβ Inhibitor
IKKβ-IN-1 is a selective inhibitor of IkappaB kinase beta (IKK-β), exhibiting an IC50 of 0.20 μM. This compound effectively reduces the production of pro-inflammatory cytokines such as PGE2 and TNF-α in mouse macrophage cells. Additionally, IKKβ-IN-1 has demonstrated protective effects against mortality in mice subjected to septic shock, highlighting its potential for research in inflammation and immune response. -
TBK1 and IKKε Inhibitor
TBK1/IKKε-IN-6 is a selective inhibitor of TBK1 and IKKε, exhibiting IC50 values below 100 nM for both targets. This compound plays a significant role in modulating inflammatory signaling pathways by inhibiting the activation of these kinases. It is particularly useful in research focused on autoimmune diseases, cancer, and viral infections, enabling the exploration of therapeutic strategies targeting the TBK1/IKKε pathway. -
IKK Inhibitor
(E/Z)-HOIPIN-1 is a selective inhibitor of the linear ubiquitin chain assembly complex (LUBAC), targeting the IκB kinase (IKK) pathway. With an IC50 value greater than 2.8 μM, this compound effectively inhibits LUBAC-mediated NF-κB activation. Its potential applications include studies of inflammatory responses, cancer biology, and the modulation of immune signaling pathways. -
IKK-β Inhibitor
SAR113945 is a highly potent inhibitor of IKK-β, exhibiting an IC50 value of 0.4 nM. This compound is primarily utilized in research focusing on inflammatory pathways and oncogenic processes. Its efficacy makes it a valuable tool for investigating the role of IKK-β in various disease states, particularly in understanding mechanisms underlying inflammation and cancer progression. -
IKKβ Inhibitor
MLN-0415 is an inhibitor of IKKβ, a key regulator in the NF-κB signaling pathway. This compound exhibits significant anti-inflammatory activity and is instrumental in researching conditions such as arthritis and other inflammatory diseases. MLN-0415 facilitates the exploration of therapeutic strategies targeting the modulation of inflammatory responses. -
IKK-2 Inhibitor
(Rac)-PF-184 is a selective inhibitor of the inhibitor of κB kinase 2 (IKK-2) with an IC50 value of 37 nM. This compound exhibits significant anti-inflammatory properties, making it a valuable tool for research into inflammatory signaling pathways. It is suitable for studies investigating the role of IKK-2 in various biological processes and disease models. -
IKKβ Inhibitor
1-Dehydro-[10]-gingerdione functions as a selective inhibitor of IKKβ by targeting its activation loop, leading to the disruption of IKKβ-mediated phosphorylation of IκBα in macrophages stimulated with various agonists. This compound effectively inhibits LPS-induced NF-κB transcriptional activity. 1-Dehydro-[10]-gingerdione holds promise for research into NF-κB-related inflammation and autoimmune disorders. -
IKK2 Inhibitor
IKK-IN-3 is a potent and selective inhibitor of IkappaB kinase 2 (IKK2, also known as IKKβ), exhibiting IC50 values of 19 nM for IKK2 and 400 nM for IKK1 (IKKα). This compound is valuable in research focused on the regulation of the NF-kB signaling pathway, which plays a critical role in inflammation, immune responses, and cancer progression. IKK-IN-3 can be utilized to investigate the therapeutic potential of IKK2 inhibition in various disease models. -
IkappaB kinase inhibitor
CGA-JK3 is an ATP-competitive inhibitor of IκB kinase (IKKβ), effectively hindering its kinase activity. This compound inhibits the phosphorylation of IκBα in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells, demonstrating its potential in studying inflammatory signaling pathways. CGA-JK3 is useful for researchers investigating the modulation of NF-κB signaling and related biological processes. -
IKKα/β Inhibitor
GTCpFE is a selective inhibitor of IKKα/β, functioning within the NF-κB signaling pathway. This compound exhibits significant anti-inflammatory properties by preventing the nuclear translocation of the p65 subunit of NF-κB. Additionally, GTCpFE demonstrates targeted anti-cancer stem-like cell activity by impairing mammosphere formation and reducing the CD44+ CD24- immunophenotype associated with aggressive breast cancer. Its dual mechanism positions GTCpFE as a promising agent for both inflammation and cancer research. -
IKK Inhibitor
TBK1/IKKε-IN-1 is a potent dual inhibitor of TBK1 and IKKε, demonstrating IC50 values of less than 100 nM. This compound is valuable for research applications involving the modulation of inflammatory pathways and immune responses. Its inhibition of these kinases provides a tool for studying their roles in various biological processes and disease states, particularly those related to cancer and neuroinflammation. -
PI3K/PIKK Inhibitor
PI3K/PIKK-IN-2 is a potent inhibitor of the phosphoinositide 3-kinase (PI3K) and phosphoinositide-dependent kinase (PIKK) pathways. This compound demonstrates significant biological activity by modulating signaling pathways involved in cell growth, metabolism, and survival. PI3K/PIKK-IN-2 is suitable for use in research applications focused on targeted therapies, including the development of antibody-drug conjugates (ADCs). -
HDAC inhibitor
Resminostat, also known as RAS2410, is a potent inhibitor of histone deacetylase (HDAC) classes I and II. It binds to and inhibits HDACs leading to an accumulation of highly acetylated histones. -
IKK2/IKK1 inhibitor
BMS-345541 is a highly selective inhibitor of the catalytic subunits of IKK-2 and IKK-1 with IC50 of 0.3 μM and 4 μM -
HDAC4 inhibitor
Tasquinimod is an orally active antiangiogenic agent by allosterically inhibiting HDAC4 signalling. -
HDAC inhibitor
RG2833 ( is a brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3. -
JAK2/HDAC dual inhibitor
JAK/HDAC-IN-1 is a potent JAK2/HDAC dual inhibitor, exhibits antiproliferative and proapoptotic activities in several hematological cell lines. -
IKKβ kinase inhibitor
Bay 65-1942 is an ATP-competitive inhibitor that selectively targets IKKβ kinase activity. -
IKKβ inhibitor
Bay 65-1942 is an ATP-competitive inhibitor that selectively targets IKKβ kinase activity. -
IKK Inhibitor
IKK-2 inhibitor VIII is a potent and selective IKK-2 inhibitor with IC50 of 8.5 nM. -
IKK Inhibitor
GSK319347A (CAY10576) is a potent, selective, inhibitor of IKK-epsilon kinase with IC50 of 40 nM; inactive at IKK-alpha and IKK-beta.
-
HDAC6 inhibitor
ACY-1215 selectively targets and binds to HDAC6, thereby disrupting the Hsp90 protein chaperone system through hyperacetylation of Hsp90 and preventing the subsequent aggresomal protein degradation. -
HDAC Inhibitor
CI-994 is a histone deacetylase (HDAC) inhibitor and induces histone hyperacetylation in living cells. -
HDAC inhibitor
Remetinostat (SHP-141) is a hydroxamic acid-based inhibitor of histone deacetylase enzymes (HDAC) which is under development for the treatment of cutaneous T-cell lymphoma. -
NF-kB inhibitor/Proteasome activator
18α-Glycyrrhetinic acid (18α-GA) is a bioactive triterpenoid found in licorice. It shows selective inhibition of 11-HSD1 (11-hydroxysteroid dehydrogenase 1).
